CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SYS-MEL aims to identify and validate biomarkers for melanoma to improve treatment outcomes. The project focuses on understanding the biological mechanisms of melanoma progression and predicting patient responses to therapies.
Worldwide figures show that there were 160,000 incidences of melanoma in 2002, whilst 39,000 died from the disease.
These upward trends are worrying, as malignant melanoma is one of the most difficult cancers to treat, due to its ability to spread quickly and its resistance to standard chemotherapeutic agents.
In order to counteract this trend, targeted therapies that inhibit melanoma metastasis are required.
The aim of SYS-MEL is to identify and validate prognostic and predictive biomarkers for…
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, Leuven
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
ROYAL COLLEGE OF SURGEONS IN IRELAND
Ireland, Dublin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
BEATSON INSTITUTE FOR CANCER RESEARCH LBG
United Kingdom, Bearsden
Type: Research institute
Activity type: Research Organisations
SME: No
Ireland, DUBLIN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
